the discovery and development of liraglutide and semaglutide Timeline critical milestones in use of GLP-1 Battle of GLP-1 delivery technologies

[DOI] [PMC free article] [PubMed] [Google Scholar] Cnop M

Most people tolerate both well over time with proper dosing and support

Type 2 diabetes with cardiovascular or kidney risk Obesity or overweight with comorbidities, where meaningful weight loss would change your risk Obesity-related OSA or knee osteoarthritis where GLP-1s can treat upstream weight and symptoms Have we done the foundations

Gabapentin, the active ingredient, is commonly prescribed for conditions like epilepsy and nerve pain associated with shingles

A patient starting at 250 pounds may lose 50-55 pounds (22%), while someone beginning at 180 pounds might lose 25-30 pounds (15-17%) on the same doseboth represent equivalent percentage weight loss but different absolute numbers

Additionally, rapid improvements in blood sugar control in diabetic patients may unmask or allow recognition of pre-existing depression that was previously masked by metabolic dysfunction